I-Mab to Present Givastomig Phase 1 Optimal Dose Estimation Data at SITC 2024
- Poster to be presented in a late-breaking abstract session at the
Presentation Details:
- Title: Optimal dose estimation using an integrated approach from Phase I data of givastomig, a novel Claudin18.2×4-1BB bispecific antibody
- Poster #: 1474
-
Presenter:
J.A. Yanez ,I-Mab -
Session: Poster Hall,
George R. Brown Convention Center -
Session Date:
Saturday, November 9, 2024 -
Session Time:
9:00 am CDT to 8:30 pm CDT , Level 1 –Exhibit Halls AB
A full copy of the poster will be available on the
About Givastomig
Givastomig (TJ033721 / ABL111) is a bispecific antibody targeting Claudin (CLDN) 18.2-positive tumor cells. It conditionally activates T cells through the 4-1BB pathway in the tumor microenvironment where CLDN18.2 is expressed. Givastomig appears to maintain strong tumor binding and anti-tumor activity, attributable to a synergistic effect of proximal interaction with CLDN18.2 and 4-1BB, while minimizing liver toxicity and systemic immunotoxicity commonly seen with other emerging 4-1BB-based product candidates. In
The program is being jointly developed through a global partnership with ABL Bio, in which
About I-Mab
I-Mab Investor & Media Contacts
Senior Director, Investor Relations
IR@imabbio.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/i-mab-to-present-givastomig-phase-1-optimal-dose-estimation-data-at-sitc-2024-302290887.html
SOURCE